Back to Search
Start Over
The therapeutic effect of anti-CD52 treatment in murine experimental autoimmune encephalomyelitis is associated with altered IL-33 and ST2 expression levels.
- Source :
-
Journal of Neuroimmunology . May2018, Vol. 318, p87-96. 10p. - Publication Year :
- 2018
-
Abstract
- Experimental autoimmune encephalomyelitis (EAE) mice were administered with murine anti-CD52 antibody to investigate its therapeutic effect and whether the treatment modulates IL-33 and ST2 expression. EAE severity and central nervous system (CNS) inflammation were reduced following the treatment, which was accompanied by peripheral T and B lymphocyte depletion and reduced production of various cytokines including IL-33, while sST2 was increased. In spinal cords of EAE mice, while the number of IL-33 + cells remained unchanged, the extracellular level of IL-33 protein was significantly reduced in anti-CD52 antibody treated mice compared with controls. Furthermore the number of ST2 + cells in the spinal cord of treated EAE mice was downregulated due to decreased inflammation and immune cell infiltration in the CNS. These results suggest that treatment with anti-CD52 antibody differentially alters expression of IL-33 and ST2, both systemically and within the CNS, which may indicate IL-33/ST2 axis is involved in the action of the antibody in inhibiting EAE. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 01655728
- Volume :
- 318
- Database :
- Academic Search Index
- Journal :
- Journal of Neuroimmunology
- Publication Type :
- Academic Journal
- Accession number :
- 128802361
- Full Text :
- https://doi.org/10.1016/j.jneuroim.2018.02.012